Alzheimer's disease (AD) is the most common neurodegenerative disorder seen in age-
dependent dementia. There is currently no effective treatment for AD, which may be …

Results from recent clinical trials of antibodies that target amyloid-β (Aβ) for Alzheimer's
disease have created excitement and have been heralded as corroboration of the amyloid …

The ability to investigate therapeutic interventions in animal models of neurodegenerative
diseases depends on extensive characterization of the model (s) being used. There are …

Accumulation of amyloid‐β (Aβ) and fibrillary tangles, as well as neuroinflammation and
memory loss, are hallmarks of Alzheimer's disease (AD). After almost 15 years from their …

Astrocytes play crucial roles in the brain and are involved in the neuroinflammatory
response. They become reactive in response to virtually all pathological situations in the …

Although great advances in elucidating the molecular basis and pathogenesis of
Alzheimer's disease (AD) have been made and multifarious novel therapeutic approaches …

Abnormal aggregation of tau in the brain is a major contributing factor in various
neurodegenerative diseases. The role of tau phosphorylation in the pathophysiology of …

Ample epidemiological evidence suggests a strong correlation among diet, lifestyle factors
and the onset and consolidation of dementia and Alzheimer's disease (AD). It has been …

Neurodegeneration, the slow and progressive dysfunction and loss of neurons and axons in
the central nervous system, is the primary pathological feature of acute and chronic …

Aggregation of β-amyloid (Aβ) in the brain begins to occur years before the clinical onset of
Alzheimer's disease (AD). Before Aβ aggregation, concentrations of extracellular soluble Aβ …